FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	DC	20549
vvasilington,	D.O.	20070

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					1 01 00	ection c	0(11) 0	i uic	IIIVESI	inent C	ompany Act	01 1340							
1. Name and Address of Reporting Person*  Troendle August J.					2. Issuer Name and Ticker or Trading Symbol  Medpace Holdings, Inc. [ MEDP ]									ationship of Report (all applicable) Director		X 10%		Owner	
(Last) (First) (Middle) C/O MEDPACE HOLDINGS, INC. 5375 MEDPACE WAY					3. Date of Earliest Transaction (Month/Day/Year) 09/16/2022									X	Officer (give title below)		e Other below		(specify
(Street) CINCINNATI OH 45227					4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person										son			
(City)	(St		Zip)																
		Table	I - N	Non-Deriva	tive	Secu	rities	Ac	quire	ed, Di	isposed c	of, or E	Benef	icially	/ Own	ed			
Date			2. Transaction Date (Month/Day/Y	Execution Date		Code (Instr.		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 a		d (A) or r. 3, 4 a	nd 5)	Securiti Benefic Owned	. Amount of Securities Seneficially Owned Following		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code V		Amount	(A) or Price		Reported Transaction(s) (Instr. 3 and 4)		tion(s)			(Instr. 4)
Common Stock			09/16/202	22				P <sup>(1)</sup>		62,516	A	\$149	.58(2)	6,143,236		I		By Medpace Investors, LLC <sup>(3)</sup>	
Common Stock			09/19/2022					P <sup>(1)</sup>		94,119	A	\$153	.48(4)	6,237,355		I		By Medpace Investors, LLC <sup>(3)</sup>	
Common	Stock														800	6,643		D	
Table II - Derivatir (e.g., pu  1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  (Instr. 3)  3. Transaction Date (Month/Day/Year)  Date (Month/Day/Year)  (Month/Day/Year)					alls, v	ition str. 5. Numbor of Derivative Securities Acquirec (A) or Disposee of (D) (Instr. 3,		6. D Exp (Mo	ions,	convertiercisable and	7. Tit Amor Secu Unde Deriv	le and unt of rities rlying rative rity (Ins	8. I De Se (In:	Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	o C S Illy C C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	and 5	(D)	Date Exe	e rcisable	Expiration Date	Title	Amou or Numb of Share	er					

## **Explanation of Responses:**

- 1. The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August
- 2. The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from \$147.35 to \$151.65. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- 3. The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- 4. The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from \$149.50 to \$155.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

/s/ Stephen P. Ewald,

Attorney-in-Fact for August J. 09/20/2022 **Troendle** 

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.